Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles
Authors:
- Zhao WangZWZhao Wang
- Shawn RumrillSRShawn Rumrill
- Dongwei KangDKDongwei Kang
- Samuel Desta GumaSGSamuel Desta Guma
- Erik De ClercqErik De Clercq
- Christophe PannecouqueCPChristophe Pannecouque
- Chin Ho ChenCCChin Ho Chen
- Eddy ArnoldEAEddy Arnold
- Francesc Xavier RuizFrancesc Xavier Ruiz
- Xinyong LiuXLXinyong Liu
- Peng ZhanPeng Zhan
Open Access
- 30 May 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (22) , eadt8916
Abstract
HIV-1 infection is a manageable chronic condition, with non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) remaining a cornerstone of antiretroviral therapy. Nevertheless, drug resistance to existing therapeutics is a serious and immediate concern. Using structure-based and scaffold-hopping approaches, we designed evolved diarylpyrimidine analogs targeting reverse transcriptase (RT), exploiting chemical space surrounding the NNRTI-binding pocket. We identified compounds 5i3 and 5e2 , with robust antiviral efficacy against wild-type HIV-1 and rilpivirine-resistant strains. Encouragingly, in vitro selection of mutant strains with 5i3 took 39 passages to select resistance, with no phenotypic cross-resistance observed with known RT drugs. Co-crystal structures of wild-type and mutant RT with 5i3 and 5e2 revealed their resilience toward resistance mutations due to enhanced conformational flexibility and positional adaptability. 5i3 exhibited good pharmacokinetic properties and favorable safety profiles, without substantial cytochrome P450 inhibition, and excellent oral bioavailability. These derivatives represent a promising scaffold for the development of anti-HIV drugs.Keywords
This publication has 75 references indexed in Scilit:
- High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutationsProceedings of the National Academy of Sciences, 2008
- The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.2007
- hERG potassium channels and cardiac arrhythmiaNature, 2006
- Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypesJournal of Virological Methods, 2005
- HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistanceTrends in Pharmacological Sciences, 2005
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004
- Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 VariantsJournal of Medicinal Chemistry, 2004
- The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistanceJournal of Molecular Biology, 2001
- A structural basis for drug-induced long QT syndromeProceedings of the National Academy of Sciences, 2000
- Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compoundsJournal of Virological Methods, 1988